Workflow
昊帆生物(301393) - 2024 Q1 - 季度财报
HIGHFINEHIGHFINE(SZ:301393)2024-04-25 09:54

Financial Performance - Revenue for Q1 2024 was ¥91,229,728.71, a decrease of 27.14% compared to ¥125,210,000.82 in the same period last year[5] - Net profit attributable to shareholders was ¥29,828,839.74, down 17.80% from ¥36,288,001.96 year-over-year[5] - Net profit excluding non-recurring items was ¥25,769,764.03, reflecting a decline of 24.12% from ¥33,960,792.95 in the previous year[5] - Basic and diluted earnings per share decreased to ¥0.28, down 37.78% from ¥0.45 in the prior year[5] - Total operating revenue for Q1 2024 was CNY 91,229,728.71, a decrease of 27.1% compared to CNY 125,210,000.82 in the same period last year[24] - Net profit for Q1 2024 was CNY 29,828,839.74, a decline of 17.7% from CNY 36,288,001.96 in Q1 2023[25] Cash Flow and Liquidity - Operating cash flow improved significantly, with a net cash flow from operating activities of ¥23,295,794.97, compared to a negative cash flow of ¥11,994,516.75 in the same quarter last year, marking a 294.22% increase[5] - Cash and cash equivalents at the end of the reporting period amount to 1,734,899,973.95 RMB, slightly down from 1,739,510,856.63 RMB at the beginning of the period[20] - Cash flow from investment activities was negative at -$22,411,271.01, an improvement from -$45,816,287.92 in the previous period[28] - Cash flow from financing activities also showed a negative trend at -$9,629,027.59, compared to -$658,849.75 previously[28] - The ending cash and cash equivalents balance was $1,246,675,971.66, a decrease from $1,255,236,454.77 at the beginning of the period[28] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥2,312,149,453.18, a slight increase of 1.10% from ¥2,286,941,939.28 at the end of the previous year[5] - Total liabilities for Q1 2024 were CNY 79,605,794.21, up from CNY 75,077,619.91 in Q1 2023[22] - Cash and cash equivalents increased to CNY 1,981,489,807.37 from CNY 1,964,007,891.97 year-over-year[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,434[12] - The largest shareholder, Zhu Yong, holds 47.40% of shares, totaling 51,192,000 shares[12] - The company plans to repurchase shares with a total amount not less than 30 million RMB and not exceeding 60 million RMB, with a maximum repurchase price of 60 RMB per share[17] - As of March 31, 2024, the company has repurchased 200,000 shares, accounting for 0.19% of the total share capital, with a total transaction amount of 9,432,971 RMB[18] Research and Development - Research and development expenses surged by 122.67% to ¥10,389,895.99, primarily due to an increase in R&D personnel[9] - Research and development expenses for Q1 2024 were CNY 10,389,895.99, significantly higher than CNY 4,665,960.48 in Q1 2023, indicating increased investment in innovation[24] Financial Management - Interest income skyrocketed by 8,561.83% to ¥12,439,672.85, attributed to cash management of idle raised funds[9] - The company reported a financial income of CNY 12,439,672.85 in Q1 2024, compared to CNY 143,614.88 in the same period last year, reflecting improved financial management[25] - The company received government subsidies totaling ¥4,500,000.00, contributing positively to its financial performance[7] Market Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]